Comparative Pharmacology
Head-to-head clinical analysis: CYTOVENE versus MAVYRET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOVENE versus MAVYRET.
CYTOVENE vs MAVYRET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanosine analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporation into viral DNA, causing chain termination. It is phosphorylated intracellularly to ganciclovir triphosphate, which is active against cytomegalovirus (CMV).
Fixed-dose combination of glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) that directly inhibits HCV viral replication by targeting viral proteins essential for polyprotein processing and RNA replication.
Induction: 5 mg/kg IV every 12 hours for 14-21 days; maintenance: 5 mg/kg IV once daily for 7 days per week or 6 mg/kg IV once daily for 5 days per week
Three tablets (containing glecaprevir 100 mg and pibrentasvir 40 mg) taken orally once daily with food for 8 to 16 weeks depending on patient characteristics and prior treatment history.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 28-40 hours in severe renal impairment (CrCl <10 mL/min)
Glecaprevir: 6 hours; pibrentasvir: 13 hours; supports once-daily dosing.
Primarily renal excretion as unchanged drug (>90%); 1-2% biliary/fecal
Primarily fecal (92%) with unchanged drug (50.3% glecaprevir, 63.8% pibrentasvir); renal elimination is minimal (<1%).
Category C
Category C
Antiviral Agent
Antiviral Agent